Table 1.

Neuroprotection by compounds structurally similar to olanzapine^*

	LSU-31	LSU-40	LSU-42	LSU-44
	Cell viability (% Control ± SEM)
5 μM	152.8 ± 10.9*	91.7 ± 3.2	103.3 ± 2.9	111.3 ± 2.5*
10 μM	133.3 ± 5.3*	96.3 ± 4.1	120 ± 6.4*	119 ± 1.9*
20 μM	128.3 ± 4.7*	112.7 ± 3.6*	135 ± 10.4*	124 ± 0.7*
40 μM	140.8 ± 10.2*	127.3 ± 9.6*	135.7 ± 3.8*	126 ± 6.4*
80 μM	127 ± 5.1*	157.7 ± 13.2*	118 ± 4.3*	96± 5.1

^*PC12.XL cells were incubated in glutamine-free, low serum medium with various concentrations of compounds. On day 3, MTS reagent was added and cell viability measured as a function of dye conversion. Results from 4 experiments have been averaged and are expressed as percentage of control (DMSO solvent) ± the standard error of the mean (SEM). Significant differences from the control as determined with Student's t-test are indicated by asterisks (*p<0.05).